临床实践中骨髓增生异常综合征的遗传易感性
Genetic Predisposition to Myelodysplastic Syndrome in Clinical Practice.
作者信息
Schratz Kristen E, DeZern Amy E
机构信息
Division of Pediatric Oncology, Johns Hopkins University School of Medicine, Bloomberg 11379, 1800 Orleans Street, Baltimore, MD 21287, USA; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans Street, Baltimore, MD 21287, USA.
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans Street, Baltimore, MD 21287, USA; Division of Hematologic Malignancies, Johns Hopkins University School of Medicine, CRBI Room 3M87, 1650 Orleans Street, Baltimore, MD 21287-0013, USA.
出版信息
Hematol Oncol Clin North Am. 2020 Apr;34(2):333-356. doi: 10.1016/j.hoc.2019.10.002. Epub 2020 Jan 6.
Abstract
Myelodysplastic syndromes (MDSs) are a heterogeneous group of marrow failure disorders that primarily affect older persons but also occur at a lower frequency in children and young adults. There is increasing recognition of an inherited predisposition to MDS as well as other myeloid malignancies for patients of all ages. Germline predisposition to MDS can occur as part of a syndrome or sporadic disease. The timely diagnosis of an underlying genetic predisposition in the setting of MDS is important. This article delineates germline genetic causes of MDS and provides a scaffold for the diagnosis and management of patients in this context.
摘要
骨髓增生异常综合征（MDS）是一组异质性的骨髓衰竭性疾病，主要影响老年人，但在儿童和年轻人中也有较低的发病率。所有年龄段的患者对MDS以及其他髓系恶性肿瘤的遗传易感性认识都在不断增加。MDS的种系易感性可作为综合征的一部分或散发性疾病出现。在MDS背景下及时诊断潜在的遗传易感性很重要。本文阐述了MDS的种系遗传原因，并为在这种情况下患者的诊断和管理提供了一个框架。
相似文献
1
Genetic Predisposition to Myelodysplastic Syndrome in Clinical Practice.临床实践中骨髓增生异常综合征的遗传易感性
Hematol Oncol Clin North Am. 2020 Apr;34(2):333-356. doi: 10.1016/j.hoc.2019.10.002. Epub 2020 Jan 6.
2
Genetic predisposition to MDS: diagnosis and management.MDS 的遗传易感性：诊断与管理。
Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):110-119. doi: 10.1182/hematology.2019000021.
3
Genetic predisposition to MDS: clinical features and clonal evolution.MDS 的遗传易感性：临床特征和克隆演变。
Blood. 2019 Mar 7;133(10):1071-1085. doi: 10.1182/blood-2018-10-844662. Epub 2019 Jan 22.
4
Significance of Clonal Mutations in Bone Marrow Failure and Inherited Myelodysplastic Syndrome/Acute Myeloid Leukemia Predisposition Syndromes.骨髓衰竭及遗传性骨髓增生异常综合征/急性髓系白血病易感综合征中克隆性突变的意义
Hematol Oncol Clin North Am. 2018 Aug;32(4):643-655. doi: 10.1016/j.hoc.2018.03.005. Epub 2018 May 1.
5
Universal genetic testing for inherited susceptibility in children and adults with myelodysplastic syndrome and acute myeloid leukemia: are we there yet?儿童和成人骨髓增生异常综合征和急性髓系白血病中遗传性易感性的通用基因检测：我们做到了吗？
Leukemia. 2018 Jul;32(7):1482-1492. doi: 10.1038/s41375-018-0051-y. Epub 2018 Feb 27.
6
Inherited thrombocytopenia and platelet disorders with germline predisposition to myeloid neoplasia.遗传性血小板减少症和血小板疾病伴种系倾向的髓系肿瘤。
Int J Lab Hematol. 2019 May;41 Suppl 1:131-141. doi: 10.1111/ijlh.12999.
7
Germline mutations in MDS/AML predisposition disorders.胚系突变与 MDS/AML 易感疾病。
Curr Opin Hematol. 2021 Mar 1;28(2):86-93. doi: 10.1097/MOH.0000000000000633.
8
Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults.儿童和年轻成人骨髓增生异常综合征及急性髓系白血病的遗传易感性。
Leuk Lymphoma. 2016;57(3):520-36. doi: 10.3109/10428194.2015.1115041. Epub 2015 Dec 23.
9
Genetic predisposition syndromes: when should they be considered in the work-up of MDS?遗传易感性综合征：在骨髓增生异常综合征的检查中何时应考虑它们？
Best Pract Res Clin Haematol. 2015 Mar;28(1):55-68. doi: 10.1016/j.beha.2014.11.004. Epub 2014 Nov 12.
10
The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.髓系基因突变panel 在骨髓增生异常综合征和骨髓增生异常/骨髓增殖性肿瘤诊断中的应用。
Int J Lab Hematol. 2021 Dec;43(6):1501-1509. doi: 10.1111/ijlh.13659. Epub 2021 Jul 16.
引用本文的文献
1
Redox biomarker levels in patients with myelodysplastic syndrome.骨髓增生异常综合征患者的氧化还原生物标志物水平。
Biomed Rep. 2025 Jan 14;22(3):45. doi: 10.3892/br.2025.1923. eCollection 2025 Mar.
2
New-Onset Monosomy 7-Induced Pancytopenia in a 66-Year-Old Woman.一名66岁女性新发7号染色体单体所致全血细胞减少症
Cureus. 2024 Jan 29;16(1):e53159. doi: 10.7759/cureus.53159. eCollection 2024 Jan.
3
The role of genetic factors in pediatric myelodysplastic syndromes with different outcomes.遗传因素在不同预后的儿童骨髓增生异常综合征中的作用。
BMC Pediatr. 2024 Jan 8;24(1):28. doi: 10.1186/s12887-023-04492-2.
4
Clonal evolution in inherited marrow failure syndromes predicts disease progression.遗传性骨髓衰竭综合征中的克隆进化可预测疾病进展。
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):125-134. doi: 10.1182/hematology.2023000469.
5
Progress toward Better Treatment of Therapy-Related AML.在治疗相关性急性髓系白血病（AML）方面取得的进展。
Cancers (Basel). 2023 Mar 8;15(6):1658. doi: 10.3390/cancers15061658.
6
Myelodysplastic syndromes.骨髓增生异常综合征。
Nat Rev Dis Primers. 2022 Nov 17;8(1):74. doi: 10.1038/s41572-022-00402-5.
7
The effect of decitabine-combined minimally myelosuppressive regimen bridged allo-HSCT on the outcomes of pediatric MDS from 10 years' experience of a single center.一项单中心 10 年经验显示，地西他滨联合最小强度预处理方案桥接allo-HSCT 对儿科 MDS 结局的影响。
BMC Pediatr. 2022 May 27;22(1):312. doi: 10.1186/s12887-022-03376-1.
8
Lower risk but high risk.低风险但高风险。
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):428-434. doi: 10.1182/hematology.2021000277.
9
The clinical and functional effects of TERT variants in myelodysplastic syndrome.TERT 变体在骨髓增生异常综合征中的临床和功能影响。
Blood. 2021 Sep 9;138(10):898-911. doi: 10.1182/blood.2021011075.
10
Effect of decitabine and thalidomide on the immunological effect and bone marrow mesenchymal stem cells of patients with myelodysplastic syndrome.地西他滨和沙利度胺对骨髓增生异常综合征患者免疫效应及骨髓间充质干细胞的影响
Am J Transl Res. 2021 Apr 15;13(4):2462-2471. eCollection 2021.
本文引用的文献
1
Diamond-Blackfan Anemia Predisposing to Myelodysplastic Syndrome in Early Adulthood.钻石黑范贫血易在成年早期发展为骨髓增生异常综合征。
JCO Precis Oncol. 2017 Nov;1:1-5. doi: 10.1200/PO.17.00112.
2
, the nuclear exosome targeting component, is mutated in familial pulmonary fibrosis and is required for telomerase RNA maturation.核 exosome 靶向组件在家族性肺纤维化中发生突变，并且是端粒酶 RNA 成熟所必需的。
Genes Dev. 2019 Oct 1;33(19-20):1381-1396. doi: 10.1101/gad.326785.119. Epub 2019 Sep 5.
3
Clinical applicability of proposed algorithm for identifying individuals at risk for hereditary hematologic malignancies.提出的用于识别遗传性血液恶性肿瘤风险个体的算法的临床适用性。
Leuk Lymphoma. 2019 Dec;60(12):3020-3027. doi: 10.1080/10428194.2019.1630618. Epub 2019 Jul 5.
4
ETV6-related thrombocytopenia and leukemia predisposition.ETV6 相关血小板减少症和白血病易感性。
Blood. 2019 Aug 22;134(8):663-667. doi: 10.1182/blood.2019852418. Epub 2019 Jun 27.
5
DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease.髓系肿瘤中的 DDX41 突变与男性性别、TP53 突变和高危疾病相关。
Am J Hematol. 2019 Jul;94(7):757-766. doi: 10.1002/ajh.25486. Epub 2019 May 7.
6
Germline deletion of in familial acute lymphoblastic leukemia.家族性急性淋巴细胞白血病中 的胚系缺失。
Blood Adv. 2019 Apr 9;3(7):1039-1046. doi: 10.1182/bloodadvances.2018030635.
7
High prevalence of cancer-associated TP53 variants in the gnomAD database: A word of caution concerning the use of variant filtering.gnomAD 数据库中癌症相关 TP53 变异的高发生率：关于使用变异过滤需谨慎。
Hum Mutat. 2019 May;40(5):516-524. doi: 10.1002/humu.23717. Epub 2019 Mar 28.
8
Hematologic malignancies and Li-Fraumeni syndrome.血液系统恶性肿瘤与李-弗劳梅尼综合征。
Cold Spring Harb Mol Case Stud. 2019 Feb 1;5(1). doi: 10.1101/mcs.a003210. Print 2019 Feb.
9
Genetic predisposition to MDS: clinical features and clonal evolution.MDS 的遗传易感性：临床特征和克隆演变。
Blood. 2019 Mar 7;133(10):1071-1085. doi: 10.1182/blood-2018-10-844662. Epub 2019 Jan 22.
10
Bone Marrow Morphology Associated With Germline Mutations in Patients With Familial Platelet Disorder With Associated Myeloid Malignancy.伴有骨髓恶性肿瘤的家族性血小板疾病患者中与种系突变相关的骨髓形态学
Pediatr Dev Pathol. 2019 Jul-Aug;22(4):315-328. doi: 10.1177/1093526618822108. Epub 2019 Jan 2.
Zotero 插件